Current Research

Charles T. Campbell Ophthalmic Microbiology Laboratory
Bibliography 1998 - 2008

1. Siamak NM, Kowalski RP, Thompson PP, Romanowski EG, Shanks RM, Gordon YJ. RPS Adeno Detector. Ophthalmology. 2009 (In Press).

2. Romanowski EG, Gordon YJ. Update on antiviral treatment for adenoviral ocular infections. Am J Ophthalmol. 2008;146:635-367.

3. Thompson PP, Kowalski RP, Shanks RM, Gordon YJ. Validation of real-time PCR for laboratory diagnosis of Acanthamoeba keratitis. J Clin Microbiol. 2008;46:3232-3236.

4. Romanowski EG, Mah FS, Kowalski RP, Yates KA, Gordon YJ. Benzalkonium chloride enhances the antibacterial efficacy of gatifloxacin in an experimental rabbit keratitis model. J Oc Pharm Ther. 2008;24:380-384.

5. Kalivoda EJ, Stella NA, O’Dee DM, Nau GJ, Shanks RM. The cAMP-dependent catabolite repression system of Serratia marcescens mediates biofilm formation through regulation of type 1 fimbriae. Appl Environ Microbiol. 2008;74:3461-3470.

6. Kowalski RP, Romanowski EG, Mah FS, Sasaki H, Fukuda M, Gordon YJ. A comparison of moxifloxacin and levofloxacin topical prophylaxis in a fluoroquinolone-resistant Staphylococcus aureus rabbit model. Jpn J Ophthalmol. 2008;52(3):211-216.

7. Shanks RM, Meehl M, Brothers KM, Martinez RM, Donegan NP, Graber ML, Cheung AL, O’Toole GA. Genetic evidence for an alternative citrate-dependent biofilm formation pathway of Staphylococcus aureus dependent on fibronectin binding proteins and the GraRS two-component regulatory system. Infection and Immunity. 2008;76:2469-2477.

8. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Topical 0.5% moxifloxacin prevents endophthalmitis in an intravitreal injection rabbit model. J Oc Pharm Ther. 2008;24:1-7.

9. Stella NA, Kalivoda EJ, O’Dee DM, Nau GJ, Shanks RM. Catabolite repression control of flagellum production by Serratia marcescens. Res. Microbiol. 2008;159:562-568.

10. Medina AA, Shanks RM, Kadouri DE. Development of a novel system for isolating genes involved in predator-prey interactions using host independent derivatives of Bdellovibrio bacteriovorus 109J.  BMC Microbiology 2008;8:33.

11. Horzempa J, Carlson Jr. PE, O’Dee DM, Shanks RMQ, Nau GJ. Global transcriptional response to mammalian temperature provides new insight into Francisella tularensis pathogenesis. BMC Microbiology 2008;8:172.

12. O'Brien T, Arshinoff SA, Mah FS. Perspectives on antibiotics for postoperative endophthalmitis prophylaxis: potential role of moxifloxacin.  J Cataract Refract Surg. 2007;33:1790-1800.

13. Mah FS. Evaluation of the effects of olopatadine ophthalmic solution, 0.2% on the ocular surface of patients with allergic conjunctivitis and dry eye. Curr Med Res Opin. 2007 Dec 31.

14. Abelson MB, Spangler DL, Epstein AB, Mah FS, Crampton HJ. Efficacy of once-daily olopatadine 0.2% ophthalmic solution compared to twice-daily olopatadine 0.1% ophthalmic solution for the treatment of ocular itching induced by conjunctival allergen challenge. Curr Eye Res. 2007;32:1017-1122.

15. Nwanegbo EC, Romanowski EG, Gordon YJ, Gambotto A. Efficacy of topical immunoglobulins (IG) against experimental adenoviral ocular infection. Invest Ophthalmol Vis Sci. 2007;48:4171-4176.

16. Rhee SS, Mah FS. Comparison of tobramycin 0.3%/dexamethasone 0.1% and tobramycin 0.3%/loteprednol 0.5% in the management of blepharo-keratoconjunctivitis. Advances in Therapy. 2007;24:60-67.

17. Mah FS, Romanowski EG, Kowalski RP, Yates KA, Gordon YJ. Zymar (Gatifloxacin 0.3%) demonstrates excellent gram-negative activity against Serratia marcescens and Pseudomonas aeruginosa in a New Zealand white rabbit keratitis model. Cornea. 2007;26:585-588.

18. Mah FS, Rosenwasser LJ, Townsend WD, Greiner JV, Bensch G. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin. 2007 May 18.

19. Shanks RM, Stella NA, Kalivoda EJ, O’Dee D, Nau GJ. A Serratia marcescens OxyR homolog mediates surface attachment and biofilm formation.  J. Bacteriol 2007;189:7262-7272.

20. Kowalski RP, Thompson PP, Kinchington PR, Gordon YJ. Evaluation of the SmartCycler II system for real-time detection of viruses and Chlamydia from ocular specimens.
Arch Ophthalmol. 2006 Aug;124(8):1135-9.

21. Romanowski EG, Yates KA, Teuchner B, Nagl M, Irschick EU, Gordon YJ. N-chlorotaurine is an effective antiviral agent against adenovirus in vitro and in the Ad5/NZW rabbit ocular model.
Invest Ophthalmol Vis Sci. 2006 May;47(5):2021-6.

22. Mah FS, Romanowski EG, Dhaliwal DK, Yates KA, Gordon YJ.Role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis in experimental in vivo studies.
J Cataract Refract Surg. 2006 Feb;32(2):264-8.

23. Harvey SA, Romanowski EG, Yates KA, Gordon YJ.Adenovirus-directed ocular innate immunity: the role of conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic human defensin-alpha.
Invest Ophthalmol Vis Sci. 2005 Oct;46(10):3657-65.

24. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox (moxifloxacin 0.5%) is non-toxic and effective in preventing endophthalmitis in a rabbit model.
Am J Ophthalmol. 2005 Sep;140(3):497-504.

25. Gordon YJ, Romanowski EG, McDermott AM.A review of antimicrobial peptides and their therapeutic potential as anti-infective drugs.
Curr Eye Res. 2005 Jul;30(7):505-15. Review.

26. Kowalski RP, Yates KA, Romanowski EG, Karenchak LM, Mah FS, Gordon YJ. An ophthalmologist's guide to understanding antibiotic susceptibility and minimum inhibitory concentration (MIC) data. Ophthalmology. 2005 Nov;112(11):1987.

27. Mah FS, Romanowski EG, Dhaliwal DK, Yates KA, Gordon YJ. The role of topical fluoroquinolones on the pathogenesis of diffuse lamellar keratitis (DLK) in experimental in vivo studies. J Cataract Refract Surg. 2005.

28. Harvey SAK, Romanowski EG, Yates KA, Gordon YJ. Ocular innate immunity protects against certain adenoviral infections via conjunctival defensin-like chemokines (IP-10, I-TAC) and phagocytic human defensin alpha. Invest Ophthalmol Vis Sci 2005;46:3657-3665.

29. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Intracameral Vigamox® (0.5% moxifloxacin) is non-toxic and effective in preventing endophthalmitis in a rabbit model. Am J Ophthalmol. 2005;140:497-504.

30. Kowalski RP. Dhaliwal DK. Ocular bacterial infections: current and future treatment options. Expert Review of Antiinfective Therapy. 2005;3:131-139.

31. Gordon YJ, Huang LC, Romanowski EG, Yates KA, Proske RJ, McDermott AM. Human cathelicidin (LL-37), a multi-functional peptide, is expressed by ocular surface epithelia and has potent antibacterial and antiviral activity. Cur Eye Res. 2005;30:385-394.

32. Romanowski EG, Mah FS, Yates KA, Kowalski RP, Gordon YJ. The successful treatment of gatifloxacin-resistant Staphylococcus aureus keratitis with Zymar® (Gatifloxacin 0.3%) in a NZW Rabbit Model. Am J Ophthalmol. 2005;139:867-877.

33. Kinchington PR, Romanowski EG, Gordon YJ. Prospects for antivirals to adenoviruses. J. Antimicrob Chemother. 2005;55:424-429.

34. Romanowski EG, Pless P, Yates KA, Gordon YJ. Topical cyclosporine A inhibits subepithelial immune infiltrates but also promotes viral shedding in experimental adenovirus models. Cornea. 2005;24:86-91.

35. Romanowski EG, Bartels SP, Vogel R, Wetherall NT, Hodges-Savola C, Kowalski RP, Yates KA, Kinchington PR, Gordon YJ. Feasibility of an antiviral clinical trial requiring cross-country shipment of conjunctival adenovirus cultures and recovery of infectious virus. Cur Eye Res. 2004;29:195-199.

36. Rhee MK, Kowalski RP, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. A laboratory evaluation of antibiotic therapy for ciprofloxacin-resistant Pseudomonas aeruginosa. Am J Ophthalmol. 2004;138:226-230.

37. Kowalski RP, Romanowski EG, Mah FS, Yates KA, Gordon YJ. Topical prophylaxis with moxifloxacin prevents endophthalmitis in a rabbit model. Am J Ophthalmol. 2004;138:33-37.

38. Mah FS. Fourth-generation fluoroquinolones: new topical agents in the war on ocular bacterial infections. Current Opinion in Ophthalmology. 2004;15:316-320.

39. Kowalski RP, Karenchak LM, Romanowski EG. Infectious Disease: Changing antibiotic susceptibility. In: Foulks GN Gardler RG, ed. Ophthalmology Clinics of North America, Cornea and External Disease. Philadelphia: W. B. Saunders Company; 2003:1-9.

40. Mah FS. New antibiotics for bacterial infections. In: Foulks GN Gardler RG, ed. Ophthalmology Clinics of North America. 2003:11-27.

41. Kowalski RP, Dhaliwal DK, Karenchak LM, Romanowski EG, Mah FS, Ritterband DC, Gordon YJ. Gatifloxacin and moxifloxacin: An in vitro susceptibility comparison to levofloxacin, ciprofloxacin, and ofloxacin using bacterial keratitis isolates. Am J Ophthalmol. 2003;136:500-505.

42 . Gordon YJ, Yates KA, Mah FS, Romanowski EG. The Effects of Xalatan® On the recovery of ocular HSV-1 in the induced reactivation & spontaneous shedding rabbit models. J Oc Pharm Ther. 2003;19:233-245.

43. Keverline MR, Kowalski RP, Dhaliwal DK. In vitro comparison of ciprofloxacin, ofloxacin, and povidone-iodine for surgical prophylaxis. J Cataract Refract Surg. 2002;28:915-91.

44. Kowalski RP, Karenchak LM, Shah C, Gordon JS. ELVIS: a new 24-hour culture test for detecting herpes simplex virus from ocular samples. Arch Ophthalmol. 2002;120:960-962.

45. Mather R, Karenchak LM, Romanowski EG, Kowalski RP. 4th Generation fluoroquinolones: New weapons in the arsenal of ophthalmic antibiotics. Am J Ophthalmol. 2002;133:463-466.

46. Romanowski EG, Yates KA, Gordon YJ. Topical corticosteroids of limited potency promote adenovirus replication in the Ad5/NZW rabbit ocular model. Cornea. 2002;21:289-291.

47. Romanowski EG, Yates KA, Gordon YJ. Antiviral prophylaxis with twice daily topical cidofovir protects against challenge in the adenovirus type 5/New Zealand rabbit ocular model. Antiviral Res. 2001;52:275-280.

48. Kowalski RP, Sundar-Raj CV, Romanowski EG, Gordon YJ. The disinfection of contact lenses contaminated with adenovirus. Am J Ophthalmol. 2001;132:777-779.

49. Kowalski RP, Pandya AN, Karenchak LM, Romanowski EG, Husted RC, Ritterband DC, Shah MK, Gordon YJ. An in vitro resistance study of levofloxacin, ciprofloxacin and ofloxacin using keratitis isolates of Staphylococcus aureus and Pseudomonas aeruginosa. Ophthalmol. 2001;108:1826-1829.

50. Dhaliwal DK, Romanowski EG, Yates KA, Hu D, Mah F, Fish DN, Gordon YJ. Valacyclovir inhibits recovery of ocular HSV-1 following experimental reactivation by LASIK. J Cataract Refract Surg. 2001;27:1288-1293.

51. Romanowski EG, Yates KA, Gordon YJ. Short term treatment with a potent topical corticosteroid of an acute ocular adenoviral infection in the New Zealand white rabbit. Cornea. 2001;20:657-660.

52. Romanowski EG, Gordon YJ, Araullo-Cruz T, Yates KA, Kinchington PR. The antiviral resistance and replication of cidofovir-resistant adenovirus variants in the New Zealand white rabbit ocular model. Invest Ophthalmol Vis Sci. 2001;42:1812-1815.

53 . Kowalski RP, Romanowski EG, Yates KA, Gordon YJ. Lomefloxacin is an effective treatment for experimental bacterial keratitis. Cornea. 2001;20:306-308.

54. Dhaliwal DK, Romanowski EG, Yates KA, Hu D, Goldstein M, Gordon YJ. Experimental laser assisted in-situ keratomileusis induces the reactivation of latent herpes simplex virus. Am J Ophthalmol. 2001;131:506-507.

55. Gordon YJ. Vancomycin prophylaxis and emerging resistance: are ophthalmologists the villains? The heroes?. Am J Ophthalmol. 2001;131:371-376.

56. Romanowski EG, Gordon YJ. Effects of topical diclofenac or ketorolac on the inhibitory activity of cidofovir in the Ad5/NZW rabbit model. Invest Ophthalmol Vis Sci. 2001;42:158-162.

57. Gordon YJ. The evolution of antiviral therapy for external ocular viral infections over twenty-five years. Cornea.2000;19:673-680.

58. Romanowski EG, Gordon YJ. Efficacy of topical cidofovir on multiple adenoviral serotypes in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 2000;41:460-463.

59. Eller AW, Friberg TR, Mah F. Migration of silicone oil into the brain: a complication of intraocular silicone oil for retinal tamponade. Am J Ophthalmol.. 2000;129:685-688.

60. Dhaliwal DK, Romanowski EG, Yates KA, Barnhorst DA, Goldstein M, Deeter R, Fish DN, Gordon YJ. Valacyclovir inhibits recovery of ocular HSV-1 following experimental reactivation by excimer laser keratectomy. Cornea. 1999;18:693-699.

61. Romanowski EG, Barnhorst DA, Kowalski RP, Gordon YJ. The survival of herpes simplex virus in multidose office ophthalmic solutions. Am J Ophthalmol. 1999;128:239-240.

62. Kowalski RP, Karenchak LM, Romanowski EG, Gordon YJ, Community Ophthalmologists of Pittsburgh, PA. The evaluation of the shell vial technique for the detection of ocular adenovirus. Ophthalmol. 1999;106:1324-1327.

63. Romanowski EG, Bartels SP, Gordon YJ. Comparative antiviral efficacies of cidofovir, trifluridine, and acyclovir in the HSV-1 rabbit keratitis model. Invest Ophthalmol Vis Sci. 1999;40:378-384.

64. Goldstein MH, Kowalski RP, Gordon YJ. Emerging fluoroquinolone resistance in bacterial keratitis: a 5-year review. Ophthalmol. 1999;106:1313-1318.

65. Kowalski RP, Romanowski EG, Waikom B, Gordon YJ. The survival of adenovirus in multidose bottles of topical fluorescein. Am J Ophthalmol. 1998;126:835-836.

66. Gordon YJ, Araullo-Cruz T, Romanowski EG. The effects of topical NSAIDS on adenoviral replication. Arch Ophthalmol. 1998;116:900-905.

67. Dhaliwal DK, Barnhorst DA, Romanowski E, Rehkopf PG, Gordon YJ. Efficient reactivation of latent herpes simplex virus type 1 by excimer laser keratectomy in the experimental rabbit ocular model. Am J Ophthalmol. 1998;125:488-492.

68. Romanowski EG, Araullo-Cruz T, Gordon YJ. Multiple adenoviral serotypes demonstrate host range extension in the New Zealand rabbit ocular model. Invest Ophthalmol Vis Sci. 1998;39:532-536.

69. Kowalski RP, Karenchak LM, Gordon YJ. Comparison of ciprofloxacin and ofloxacin using human corneal susceptibility levels. Cornea. 1998;17:282-7.

70. Kowalski RP. Karenchak LM. Warren BB. Eller AW. Time-kill profiles of Enterococcus to antibiotics used for intravitreal therapy. Ophthal Surg Lasers. 1998;29:295-299.